Authors
Latest:
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic MelanomaThis clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Latest:
Unmet Needs and Future Directions in CLLDrs Bishop and Bank close by outlining remaining unmet needs in CLL, emerging regimens, and hopes for the future of care.
Latest:
Investigational Treatment Approach Effective, Safe and Inexpensive in a Type of Prostate Cancer, Says ExpertThus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
Latest:
Treatment Response and Duration of Therapy in Transplant-Ineligible NDMMClosing out their module on transplant-ineligible NDMM management, expert panelists consider best practices regarding duration of therapy and adjustments to drug regimens.
Latest:
John Heymach, MD, PhD, Discusses the Use of Adjuvant Immunotherapy for Patients With NSCLCCancerNetwork® sat down with John Heymach, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk adjuvant immunotherapy for recurrence-free survival in resected non–small cell lung cancer.
Latest:
Jonathan Thompson, MD, MS, on AEs and Limitations Reported in the Phase 2 BGBC008 StudyThe trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI–refractory composite AXL (cAXL)–positive non–small cell lung cancer.
Latest:
Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsExperts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
Latest:
Cutaneous T-Cell Lymphoma: Current and Emerging TherapiesJulia Dai, MD, and Madeleine Duvic, MD, present a comprehensive review of the current state of research and treatment in cutaneous T-cell lymphoma.
Latest:
Advanced Penile Cancer Presenting With Renal Failure“MK,” a man aged 67 years, presented with fatigue and nausea to his primary care physician. CT staging scans confirmed the primary tumor and a suspicious left 1.2-cm inguinal lymph node but no distant metastases. MRI of the pelvis revealed complete replacement of the penis with tumor as well as invasion into the scrotum and bilateral groin soft tissue; additionally, early pubic bone invasion was present, with left groin lymphadenopathy. Biopsy verified squamous cell carcinoma of the penis, and discussion with the multidisciplinary team uroradiologist confirmed bony invasion.
Latest:
Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head MassRohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.
Latest:
Frontline Forum: Real-World Practice in Newly Diagnosed Multiple MyelomaExperts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Latest:
Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MMPanelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma.
Latest:
Adverse Effects Associated with SBRT in Patients With HCCThe panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.
Latest:
The Role of Next-Generation Sequencing in Patients With Neuroendocrine TumorsPanelists discuss how next-generation sequencing can identify actionable mutations and molecular alterations in neuroendocrine tumors, potentially guiding personalized treatment decisions and clinical trial eligibility while advancing our understanding of tumor biology.
